{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:35:34Z","timestamp":1761100534483},"reference-count":38,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2001,12,21]],"date-time":"2001-12-21T00:00:00Z","timestamp":1008892800000},"content-version":"vor","delay-in-days":155,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2001,7,19]]},"abstract":"<jats:p> <jats:bold>Abstract<\/jats:bold> <\/jats:p><jats:p> <jats:italic>Background:<\/jats:italic> High\u2010dose therapy (HDT) with autologous bone marrow or blood cell transplantation for the treatment of lymphoma commenced at Peter MacCallum Cancer Institute in 1986.<\/jats:p><jats:p> <jats:italic>Aim:<\/jats:italic> To examine the patient characteristics and outcomes of patients with non\u2010Hodgkin\u2019s lymphoma (NHL) and Hodgkin\u2019s disease (HD) treated with HDT and autologous transplantation at our Institute in the first 10 years of the service (1986\u201395).<\/jats:p><jats:p> <jats:italic>Methods:<\/jats:italic> A retrospective analysis was performed examining patient characteristics, prior chemotherapy regimens, pretransplant disease status, HDT regimen, source of stem cells, time for haematopoietic recovery, complications of transplantation, response rates, overall survival (OS) and progression\u2010free survival (PFS).<\/jats:p><jats:p> <jats:italic>Results:<\/jats:italic> Sixty\u2010seven patients with NHL were treated with an estimated 5\u2010year OS rate of 44% (95% confidence interval (CI) 32\u201356%) and PFS rate of 34% (95% CI 21\u201344%). Factors independently predictive of an unfavourable PFS on multivariate analyses were presence of constitutional symptoms at transplant (<jats:italic>P<\/jats:italic> &lt; 0.002) and chemotherapy\u2010resistant disease at transplant (<jats:italic>P<\/jats:italic> = 0.02). Twenty\u2010three patients with HD were treated with a 5\u2010year predicted OS rate of 74% (95% CI 56\u201392%) and PFS rate of 57% (95% CI 36\u201377%). There was no difference in PFS for HD patients who relapsed either within 12 months of completion of front\u2010line therapy or after this time (<jats:italic>P<\/jats:italic> = 0.5). The transplant\u2010related mortality for the entire cohort was 17%, with a progressive decrease over time.<\/jats:p><jats:p> <jats:italic>Conclusion:<\/jats:italic> HDT with autologous transplanta\u2010 tion achieves durable PFS and OS in patients with lymphoma. Improved patient selection, therapy modifications according to prognostic factors and ongoing improvements in supportive care should improve outcomes further. (Intern Med J 2001; 31: 279\u2013289)<\/jats:p>","DOI":"10.1046\/j.1445-5994.2001.00066.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T02:15:21Z","timestamp":1047435321000},"page":"279-289","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["High\u2010dose therapy and autologous transplantation for lymphoma: The Peter MacCallum Cancer Institute experience"],"prefix":"10.1111","volume":"31","author":[{"given":"A. J.","family":"Dowling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. M.","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. H.","family":"Januszewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Juneja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. F.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Gates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. G.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,21]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304083281404"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_6_5_2","first-page":"3562","article-title":"The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial.","volume":"92","author":"Blay J","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010497"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008291723029"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.2.534"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.10.1846"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.10.1615"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.437976.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.588"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/5.suppl_2.S143"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.445"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199705013361804"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1131"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504203321601"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2796"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"e_1_2_6_20_2","unstructured":"SchmitzN SextroM PfistnerBet al.High\u2010dose therapy followed by hematopoietic stem cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: Final results of a randomized GHSG and EBMT trial (HD\u2010R1). Proc Am Soc Clin Oncol 1999; 18: A3 (Abstract)."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.4.704"},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood.V83.5.1193.1193","article-title":"Intensive therapy with cyclophosphamide, carmustine, etoposide +\/\u2013 cisplatin, and autologous bone marrow transplantation for Hodgkin\u2019s disease in first relapse after combination chemotherapy.","volume":"83","author":"Reece DE","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood.V85.5.1381.bloodjournal8551381","article-title":"High\u2010dose chemotherapy with or without total body irradiation followed by autologous bone marrow and\/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin\u2019s disease: Results in 85 patients with analysis of prognostic factors.","volume":"85","author":"Nademanee A","year":"1995","journal-title":"Blood"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood.V89.3.801","article-title":"High\u2010dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin\u2019s disease: Analysis of the Stanford University results and prognostic indicies.","volume":"89","author":"Horning SJ","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.222"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.534"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3101"},{"key":"e_1_2_6_28_2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.V86.2.451.bloodjournal862451","article-title":"High\u2010dose cyclophosphamide, carmustine [BCNU], and etoposide [VP16\u2010213] with or without cisplatin [CBV+P] and autologous transplantation for patients with Hodgkin\u2019s disease who fail to enter a complete remission after combination chemotherapy.","volume":"86","author":"Reece DE","year":"1995","journal-title":"Blood"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/4.suppl_1.S21"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/oxfordjournals.annonc.a058043","article-title":"Prolonged disease\u2010free survival after high\u2010dose sequential chemo\u2010radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin\u2019s disease.","volume":"2","author":"Gianni AM","year":"1991","journal-title":"Ann Oncol"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.7.2233"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1997.tb02200.x"},{"key":"e_1_2_6_33_2","unstructured":"Nivison\u2010SmithI&HawkinsT.Australasian Bone Marrow Transplant Recipient Registry: Annual Report 1998. Sydney: Australasian Bone Marrow Transplant Recipient Registry 1999."},{"key":"e_1_2_6_34_2","doi-asserted-by":"crossref","unstructured":"National Cancer Institute sponsored study of classifications of non\u2010Hodgkin\u2019s lymphoma.Cancer 1982; 49: 2112\u201335.","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701308"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.423"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706113162401"},{"key":"e_1_2_6_38_2","unstructured":"BoslyA SonetA SallesGet al.Superiority of late over early intensification in relapsing\/refractory aggressive non\u2010Hodgkin\u2019s lymphoma. A randomized study from the GELA: LNH RP 93. Blood 1997; 90 (Suppl. 1): 594 (Abstract)."},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.12.2351"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1445-5994.2001.00066.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1445-5994.2001.00066.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T10:00:46Z","timestamp":1697623246000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1445-5994.2001.00066.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7,19]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,7,19]]}},"alternative-id":["10.1046\/j.1445-5994.2001.00066.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1445-5994.2001.00066.x","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7,19]]},"assertion":[{"value":"2001-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}